Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.
复制标题
DOI：
10.3332/ecancer.2016.626
复制
发表时间：
2016
影响因子：
1.8
通讯作者：
Prabhakaran PK
中科院分区：
文献类型：
--
作者：
Lokadasan R;James FV;Narayanan G;Prabhakaran PK
上皮性卵巢癌（EOC）仍然是一个临床挑战，需要优化目前可用的治疗方法，并紧急开发新的治疗策略。最近，人们对卵巢癌的分子特征和肿瘤微环境有了更深入的了解。这促进了与化疗同时使用或作为维持的各种靶向药物的开发。大多数研究探索了肿瘤血管生成的途径。在III期试验中，贝伐珠单抗显示无进展生存期有统计学显著改善，尽管在选定的高危病例中总生存期没有改善。虽然发现几种多靶点酪氨酸激酶抑制剂是有用的，但必须权衡毒性和生存益处。聚ADP核糖聚合酶（PARP）抑制剂是另一种被发现对乳腺癌1、早发型（BRCA）阳性卵巢癌有效的奇妙分子。几种靶向Her 2、Wee酪氨酸激酶、PIP 3/AKT/mTR信号通路、叶酸受体的新分子正在开发中，可能在未来提供更多机会。这篇文章的重点是靶向药物，成功地铺平了道路，在上皮性卵巢癌的管理和新的分子，可能会提供治疗的机会，在未来。
Epithelial ovarian cancer (EOC) remains a clinical challenge and there is a need to optimise the currently available treatment and to urgently develop new therapeutic strategies. Recently, there has been improved understanding of the molecular characteristics and tumour microenvironment of ovarian cancers. This has facilitated the development of various targeted agents used concurrently with chemotherapy or as maintenance. Most of the studies have explored the tumour angiogenesis pathways. In phase-III trials, bevacizumab showed a statistically significant improvement in progression-free survival, although there was no improvement in overall survival in selected high-risk cases. Although several multi-targeted tyrosine kinase inhibitors were found to be useful, the toxicity and survival benefit has to be weighed. Poly ADP ribose polymerase (PARP) inhibitors have been another marvellous molecule found to be effective in breast cancer 1, early onset (BRCA)-positive ovarian cancers. Several newer molecules targeting Her 2, Wee tyrsine kinases, PIP3/AKT/mTR-signalling pathways, folate receptors are under development and may provide additional opportunities in the future. This article focuses on the targeted agents that have successfully paved the way in the management of epithelial ovarian cancer and the newer molecules that may offer therapeutic opportunities in the future.